Background In human immunodeficiency virus (HIV)-infected patients on combination
antiretroviral therapy (cART), lipodystrophy shares many similarities with metabolic …

Background Lipodystrophy (peripheral lipoatrophy, central fat accumulation, and
lipomatosis) is a common and disfiguring problem in adult patients with HIV-1 infection on …

Background HIV-infected patients on long-term highly active antiretroviral therapy often
present peculiar patterns of fat redistribution, referred to as lipodystrophy. In spite of recent …

Objective: Antiretrovirals, especially thymidine-analogue nucleoside reverse transcriptase
inhibitors (tNRTIs), may cause the mitochondrial damage in adipose tissue that has been …

Context: The expression of adipogenic genes in sc adipose tissue has been reported to be
lower among patients with HIV-associated lipoatrophy than HIV-uninfected controls. It is …

Background HIV lipodystrophy–characterized by peripheral lipoatrophy, with or without
central fat accumulation–confers increased metabolic risk. However, the functional activity of …

HIV-related lipodystrophy is a frequent complication in HIV-infected individuals on
antiretroviral therapy (ART). Although it has been initially associated with the use of protease …

Patients infected with HIV are now developing a new condition called HIV lipodystrophy
syndrome. This condition is characterized by high blood cholesterol and triglyceride …

Lipodystrophy can be avoided by selecting therapies with benign effects on adipose tissue.
Switching from certain HIV protease inhibitors may normalize the metabolic profile fairly …

Antiretroviral therapy in human immunodeficiency virus (HIV)-positive patients can induce a
lipodystrophy syndrome of peripheral fat wasting and central adiposity, dyslipidemia, and …